Solid Biosciences (SLDB) said late Tuesday the US Food and Drug Administration cleared the company's investigational new drug application for SGT-212 to treat Friedreich's ataxia.
The company expects to begin a phase 1b clinical trial of SGT-212 in H2 with study participants to be followed out to five years after receiving the treatment.
Friedreich's ataxia is a degenerative disease caused by inadequate levels of the frataxin protein.
Solid Biosciences shares rose 13% in after-hours activity.
Price: 4.44, Change: +0.52, Percent Change: +13.27
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.